💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Triazolam

CHEMBL646 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
343.2 g/mol
LogP
2.4
Phase
4

This short-acting benzodiazepine is prescribed for the short-term treatment of severe insomnia, particularly trouble falling asleep. It works by enhancing the calming effects of GABA in the brain to induce sleep. Due to its rapid action and potential for next-day memory problems, dependence, and rebound insomnia, it is recommended only for very short-term use.

น้ำหนักโมเลกุล

343.2000 g/mol

LogP

2.40

TPSA

43.10 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

Pain Management Schizophrenia Generalized Anxiety Disorder Chronic Pain

Pharmacokinetics (PK)

Pharmacodynamics (PD)

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1Cl)=NC2

                

                

                
                

                    
InChI

                    
InChI=1S/C17H12Cl2N4/c1-10-21-22-16-9-20-17(12-4-2-3-5-14(12)19)13-8-11(18)6-7-15(13)23(10)16/h2-8H,9H2,1H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C17H12Cl2N4

                    

                    
                    

                        
HBD / HBA

                        
- / 3

                    

                    
                    

                        
พันธะที่หมุนได้

                        
1

                    

                    
                    
                    

                        
อะตอมหนัก

                        
23

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
This short-acting benzodiazepine is prescribed for the short-term treatment of severe insomnia, particularly trouble falling asleep. It works by enhancing the calming effects of GABA in the brain to induce sleep. Due to its rapid action and potential for next-day memory problems, dependence, and rebound insomnia, it is recommended only for very short-term use.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Triazolam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL646.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 5556.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.